Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Document › Details

R-Biopharm AG. (10/29/15). "Press Release: Takeover [of] the business operations of GeneWake GmbH". Darmstadt.

Organisations Organisation R-Biopharm AG
  Group R-Biopharm (Group)
  Organisation 2 GeneWake GmbH
  Group R-Biopharm (Group)
Products Product companion diagnostic test
  Product 2 molecular diagnostics
Index term Index term GeneWake–R-Biopharm: investment, 201510 acquisition of GeneWake GmbH which had filed for bankruptcy in February 2015
Person Person Apostel, Frank (R-Biopharm 201311 Director Business Development)
     


R-Biopharm AG, one of the world's leading suppliers of reliable test systems for clinical diagnostics is taking over the business operations of GeneWake GmbH and reinforcing its field of Companion Diagnostics.

R-Biopharm AG has many years of experience in the development of test systems for clinical diagnosis. It is a company with a strong growth in sales and a leader in the field of infection diagnosis, in particular the fast detection of noroviruses.

Molecular biology detection methods form an essential part of medical laboratory diagnosis. Early detection is a great advantage for the effective treatment of diseases and is decisive for the course of the illness. Molecular diagnosis enables early and specific diagnosis through direct detection of the DNA and RNA of the pathogen, which enables targeted and individual therapeutic treatment of the patient. Personalized medicine takes into account the individual circumstances which go beyond the functional diagnosis of the disease. The different genetic compositions of patients require individually tailored treatments and adaptation of the medication in order to achieve the best possible cure. Companion Diagnostics is an important step towards personalized health care. In simple terms, Companion Diagnostics are tests which indicate whether the planned treatment will be successful in the specific case.

Companion Diagnostics provide tailor-made treatment which provides each patient with the right medication or treatment at the right time and eliminates ineffective treatments. At the same time, with the development of these tests, R-Biopharm AG contributes to the implementation of affordable personalized treatment. The aim of R-Biopharm AG as a dependable partner for pharmaceutical and biotechnology companies, is to launch the most effective personalized treatments on the market throughout the world. Particularly in this field, there are synergies between R-Biopharm AG and the GeneWake GmbH, which was founded in Munich in 2009. GeneWake GmbH stands for the development of innovative molecular diagnostics and provides a comprehensive portfolio of platform technologies, experience in the establishment of methods and in the field of biomarker detection and validation. It has developed several innovative diagnostic tests and methods which enable individual treatment of the most important types of umor. The expertise of GeneWake GmbH reinforces the field of Companion Diagnostics of R-Biopharm AG in the development of biomarker tests and extends its portfolio.

"By the acquisition of GeneWake GmbH the field of Companion Diagnostics can be further reinforced and advanced and an even broader spectrum of innovative diagnostic test systems for a wide range of medical questions can be offered to the biotechnology and pharmaceutical industries", says Dr. Frank Apostel, Vice President Companion Diagnostics at R-Biopharm AG


Company Profile R-Biopharm AG

The globally active R-Biopharm AG has been located in Darmstadt since 1988 and is one of the world's leading suppliers of dependable test systems for clinical diagnostics and animal feed and foodstuff analysis. The products developed by R-Biopharm are characterized by their excellent quality, reliability and efficiency. With its awareness of responsibility, many years experience and a network of more than 30 subsidiaries worldwide, as well as more than 80 international sales partners, together with R-Biopharm, customers from trade and industry and state institutions find answers and solutions to their current analytical challenges.

Contact:

R-Biopharm AG
Dr. Frank Apostel
Vice President Companion Diagnostics
An der neuen Bergstrasse 17
64297 Darmstadt, Germany
Phone: +49 (0) 61 51 – 81 02-537
E-mail: f.apostel@r-biopharm.de
www.r-biopharm.com
www.companion-diagnostics.com


[ als ZUSATZINFO geholt via http://www.genewake.com/en/imprint/; ML]

http://www.genewake.com/en/imprint/

Imprint
GeneWake GmbH

Floriansbogen 2-4
82061 Neuried
Germany

Phone: +49 (0)89 744 191 66
Fax: +49 (0)89 744 191 64
E-Mail: info@genewake.com

CEO: Robert Löwe
Handelsregister München, HRB 181791
USt-Id-Nr. DE815112895

http://www.genewake.com/en/about-us/

About us
GeneWake Bild About us_bearbeitet-1
GeneWake GmbH – development of innovative molecular diagnostics

Providing a comprehensive panel of genomic services and technologies for genomics, transcriptomics, epigenetics and proteomics, GeneWake offers diagnostic kit development, companion diagnostics, biomarker detection and technology development as part of contract research or within the scope of clinical studies. Due to the company’s broad spectrum of the latest technologies and methods ranging from next generation sequencing to quantitative PCR and section bases analysis, tailored experimental design can be offered for the individual needs of each individual research question.

Proprietary developments and innovations in the field of oncology are supported by multiple awarded grants and aim to contribute to a more personalized treatment of cancer. These developments include an innovative technique to detect mutations directly on a tumor section (BMBF colorectal cancer study) and a novel blood, urine and tissue test for tumor stratification and therapy monitoring for an individual effective therapy (BMBF prostate cancer study).

GeneWake is located in Neuried near Munich and was founded in 2009.

   
Record changed: 2016-04-19

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for R-Biopharm (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top